Allelic exclusion of IgD allotypes on murine B cells.

Selective killing of normal or neoplastic B cells by antibodies coupled to the A chain of ricin. Proc Natl Acad Sci U S A (1980) 1.85

Plasmacytomas with more than one immunoglobulin kappa mRNA: implications for allelic exclusion. Proc Natl Acad Sci U S A (1981) 1.24

Physiology of IgD. I. Compensatory phenomena in B lymphocyte activation in mice treated with anti-IgD antibodies. J Exp Med (1981) 0.96

Immunoglobulin D: properties, measurement, and clinical relevance. Clin Diagn Lab Immunol (2000) 0.82

Induction of a B-lymphocyte receptor for a T cell-replacing factor by the crosslinking of surface IgD. Proc Natl Acad Sci U S A (1983) 0.77

Safety of cold polypectomy for <10mm polyps at colonoscopy: a prospective multicenter study. Endoscopy (2011) 3.91

Randomised clinical trial: low-volume bowel preparation for colonoscopy - a comparison between two different PEG-based formulations. Aliment Pharmacol Ther (2012) 2.28

A retrospective analysis of early and late outcome of biodegradable stent placement in the management of refractory anastomotic colorectal strictures. Surg Endosc (2013) 1.72

Isolation and characterization of H-2 and TL alloantigens from the surface of mouse lymphocytes. Cell Immunol (1972) 1.45

Molecular similarities between the Qa-2 alloantigen and other gene products of the 17th chromosome of the mouse. J Exp Med (1977) 1.36

Characterization of the spontaneous murine B cell leukemia (BCL1). III. Evidence for monoclonality by using an anti-idiotype antibody. J Immunol (1979) 1.18

Induction of murine B cell proliferation by insolubilized anti-immunoglobulins. J Immunol (1980) 1.13

The relationship between surface immunoglobulin isotype and the immune function of murine B lymphocytes. V. High affinity secondary antibody responses are transferred by both IgD-positive and IgD-negative memory B cells. J Immunol (1981) 1.07

The activation of murine B cells: the role of surface immunoglobulins. Immunol Rev (1980) 1.02

A phase-I study of an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT-dgA) in patients with refractory Hodgkin's lymphoma. Blood (1997) 0.96

Treatment of refractory Hodgkin's lymphoma patients with an anti-CD25 ricin A-chain immunotoxin. Leukemia (2000) 0.90

Clinical trials with an anti-CD25 ricin A-chain experimental and immunotoxin (RFT5-SMPT-dgA) in Hodgkin's lymphoma. Leuk Lymphoma (1998) 0.84

The emerging role of ricin A-chain immunotoxins in leukemia and lymphoma. Curr Top Microbiol Immunol (1998) 0.83

Balanced Propofol Sedation in Patients Undergoing EUS-FNA: A Pilot Study to Assess Feasibility and Safety. Diagn Ther Endosc (2011) 0.82

Complete sustained response of a refractory, post-transplantation, large B-cell lymphoma to an anti-CD22 immunotoxin. Ann Intern Med (1997) 0.80

Immunotoxins in the therapy of cancer: from bench to clinic. Pharmacol Ther (1994) 0.79

Evidence for a second class II (Ia) antigenic system in rats linked to RT1. Transplant Proc (1979) 0.77

Characterization of human anti-acetylcholine receptor monoclonal autoantibodies from the peripheral blood of a myasthenia gravis patient using combinatorial libraries. Clin Immunol (2000) 0.77

Donor T lymphocyte infusion following ex vivo depletion of donor anti-host reactivity by a specific anti-interleukin-2 receptor P55 chain immunotoxin. Transplant Proc (2002) 0.76

T-cell receptor expression in murine myasthenia gravis. Ann N Y Acad Sci (1993) 0.75

In vitro and in vivo inhibition of anti-gal secreting cells. Transplant Proc (2000) 0.75

Biochemical demonstration- of anti-Qa activity in an H-2.28 public specificity antiserum. Immunogenetics (1978) 0.75